US04965G1094 - Common Stock
ATRECA INC - A
NASDAQ:BCEL (3/18/2024, 8:00:01 PM)
After market: 0.1399 -0.01 (-6.73%)0.15
-0.02 (-11.76%)
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
ATRECA INC - A
835 Industrial Road,, 75 Shoreway Road, Suite C
San Carlos CALIFORNIA 94063
P: 16505952595
CEO: John A. Orwin
Employees: 90
Website: https://www.atreca.com/
It's time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today!
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Here you can normally see the latest stock twits on BCEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: